Cargando…

Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage

Primary plasma cell leukemia (PCL) has a consistently ominous prognosis, even after progress in the last decades. PCL deserves a prompt identification to start the most effective treatment for this ultra-high-risk disease. The aim of this position paper is to revisit the diagnosis of PCL according t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fernández de Larrea, Carlos, Kyle, Robert, Rosiñol, Laura, Paiva, Bruno, Engelhardt, Monika, Usmani, Saad, Caers, Jo, Gonsalves, Wilson, Schjesvold, Fredrik, Merlini, Giampaolo, Lentzch, Suzanne, Ocio, Enrique, Garderet, Laurent, Moreau, Philippe, Sonneveld, Pieter, Badros, Ashraf, Gahrton, Gösta, Goldschmidt, Hartmut, Tuchman, Sascha, Einsele, Hermann, Durie, Brian, Wirk, Baldeep, Musto, Pellegrino, Hayden, Patrick, Kaiser, Martin, Miguel, Jesús San, Bladé, Joan, Rajkumar, S. Vincent, Mateos, Maria Victoria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640034/ https://www.ncbi.nlm.nih.gov/pubmed/34857730 http://dx.doi.org/10.1038/s41408-021-00587-0

Ejemplares similares

Allogeneic Transplantation in Multiple Myeloma—Does It Still Have a Place?
por: Gahrton, Gösta, et al.
Publicado: (2020)

Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel
por: Caers, J., et al.
Publicado: (2018)

Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition
por: Granell, Miquel, et al.
Publicado: (2017)

CAR T-cell treatment of high-risk multiple myeloma: will there be a cure?
por: Gahrton, Gösta
Publicado: (2023)

Sarcoid Reactions after Chemotherapy for Hodgkin’s Lymphoma
por: Wirk, Baldeep
Publicado: (2010)

Extramedullary disease in multiple myeloma: a systematic literature review
por: Bladé, Joan, et al.
Publicado: (2022)

Early Recognition of Immune Reconstitution Inflammatory Syndrome Leads to Avoidance of Endotracheal Intubation
por: Barretto, Johan, et al.
Publicado: (2012)

Treatment of Patients with Monoclonal Gammopathy of Clinical Significance
por: Moreno, David F., et al.
Publicado: (2021)

From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives
por: Gay, Francesca, et al.
Publicado: (2018)

Gastrointestinal Tract Amyloidosis Presenting With Pneumatosis Intestinalis
por: Raghunathan, Vikram, et al.
Publicado: (2017)

2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde
por: Musto, Pellegrino, et al.
Publicado: (2021)

Outcomes of Salvage Autologous Versus Allogeneic Hematopoietic Cell Transplantation for Relapsed Multiple Myeloma After Initial Autologous Hematopoietic Cell Transplantation
por: Wirk, Baldeep, et al.
Publicado: (2013)

Neoplastic plasma cells with Auer rod‐like inclusions
por: Jakob, Nordberg Nørgaard, et al.
Publicado: (2020)

B03 CARFILZOMIB AND LENALIDOMIDE FOR PRIMARY PLASMA CELL LEUKEMIA: FINAL RESULTS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR PATIENTS AGED ≥66 YEARS
por: Musto, P., et al.
Publicado: (2023)

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network
por: Ludwig, Heinz, et al.
Publicado: (2018)

Paraskeletal and extramedullary plasmacytomas in multiple myeloma at diagnosis and at first relapse: 50-years of experience from an academic institution
por: Jiménez-Segura, Raquel, et al.
Publicado: (2022)

COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
por: Ludwig, Heinz, et al.
Publicado: (2021)

Cardiovascular adverse events in modern myeloma therapy – Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)
por: Bringhen, Sara, et al.
Publicado: (2018)

Detection of Skeletal Lesions by Whole Body Multidetector Computed Tomography in Multiple Myeloma has no Impact on Long-Term Outcomes Post Autologous Hematopoietic Cell Transplantation
por: Wirk, Baldeep, et al.
Publicado: (2012)

European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when
por: Caers, Jo, et al.
Publicado: (2018)

B02 CARFILZOMIB AND LENALIDOMIDE-BASED THERAPY FOR THE TREATMENT OF PRIMARY PLASMA CELL LEUKEMIA: RESULTS OF THE FINAL ANALYSIS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR PATIENTS AGED 18-65 YEARS
por: van de Donk, N., et al.
Publicado: (2023)

Navigating the treatment landscape in multiple myeloma: which combinations to use and when?
por: Goldschmidt, Hartmut, et al.
Publicado: (2018)

Plasma cell leukemia: another piece of the puzzle
por: Musto, Pellegrino, et al.
Publicado: (2022)

A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma
por: Navarro, Alfons, et al.
Publicado: (2015)

Melflufen: A Peptide–Drug Conjugate for the Treatment of Multiple Myeloma
por: Mateos, María-Victoria, et al.
Publicado: (2020)

International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)
por: Mateos, María-Victoria, et al.
Publicado: (2020)

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
por: Ludwig, Heinz, et al.
Publicado: (2020)

Should we measure clonal circulating plasma cells in light chain amyloidosis?
por: Sidana, Surbhi, et al.
Publicado: (2018)

Authors’ reply: Perspective: The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA
por: Schjesvold, Fredrik H, et al.
Publicado: (2022)

Lenalidomide, Melphalan, and Prednisone Association Is an Effective Salvage Therapy in Relapsed Plasma Cell Leukaemia
por: Guglielmelli, Tommasina, et al.
Publicado: (2009)

The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling
por: Díaz, Tania, et al.
Publicado: (2017)

Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up
por: Dimopoulos, Meletios A., et al.
Publicado: (2021)

An Overall Glance of Evidence Supportive of One-Hour and Two-Hour Postload Plasma Glucose Levels as Predictors of Long-Term Cardiovascular Events
por: Mann, Baldeep K., et al.
Publicado: (2019)

Outcomes of Patients with Newly Diagnosed Transplant-Ineligible Multiple Myeloma According to Clinical Trials Enrollment: Experience of a Single Institution
por: Rodríguez-Lobato, Luis Gerardo, et al.
Publicado: (2023)

Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
por: Terpos, Evangelos, et al.
Publicado: (2023)

Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network
por: Moreau, Philippe, et al.
Publicado: (2019)

Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies
por: Lejeune, Margaux, et al.
Publicado: (2020)

Amyloidogenic light chains impair plasma cell survival
por: Pick, Marjorie, et al.
Publicado: (2023)

Conditioning with melphalan 200 mg/m(2) and subsequent ASCT improves progression‐free and overall survival in elderly myeloma patients compared to standard of care
por: Afram, Gabriel, et al.
Publicado: (2022)

Hematopoietic Cell Transplantation for Primary Plasma Cell Leukemia: Results from the Center for International Blood and Marrow Transplant Research
por: Mahindra, Anuj, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_32franfcv3c8stan0jjmv9th8u